

Journal Pre-proof

Superhydrophobic polydimethylsiloxane dip-coated polycaprolactone electrospun membrane for extracorporeal membrane oxygenation

Zhuomin Jiang, Bao Tran Duy Nguyen, JeongHyeon Seo, Changgi Hong, Dongwoo Kim, Suhyun Ryu, Sohui Lee, Gyubok Lee, Young Hoon Cho, Jeong F. Kim, Kangwon Lee

PII: S0376-7388(23)00371-X

DOI: <https://doi.org/10.1016/j.memsci.2023.121715>

Reference: MEMSCI 121715

To appear in: *Journal of Membrane Science*

Received Date: 10 January 2023

Revised Date: 25 April 2023

Accepted Date: 1 May 2023

Please cite this article as: Z. Jiang, B.T.D. Nguyen, J. Seo, C. Hong, D. Kim, S. Ryu, S. Lee, G. Lee, Y.H. Cho, J.F. Kim, K. Lee, Superhydrophobic polydimethylsiloxane dip-coated polycaprolactone electrospun membrane for extracorporeal membrane oxygenation, *Journal of Membrane Science* (2023), doi: <https://doi.org/10.1016/j.memsci.2023.121715>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2023 Published by Elsevier B.V.



Graphical Abstract

Superhydrophobic polydimethylsiloxane dip-coated polycaprolactone electrospun membrane for extracorporeal membrane oxygenation

Zhuomin Jiang, Bao Tran Duy Nguyen, JeongHyeon Seo, Changgi Hong, Dongwoo Kim, Suhyun Ryu, Sohui Lee, Gyubok Lee, Young Hoon Cho*, Jeong F. Kim*, Kangwon Lee**




Figure was created using BioRender (agreement number: YZ259I72A8).

Superhydrophobic polydimethylsiloxane dip-coated polycaprolactone electrospun membrane for extracorporeal membrane oxygenation

Zhuomin Jiang^{a,b}, Bao Tran Duy Nguyen^c, JeongHyeon Seo^d, Changgi Hong^{a,b}, Dongwoo Kim^{a,b}, Suhyun Ryu^{a,b}, Sohui Lee^{a,b}, Gyubok Lee^{a,b}, Young Hoon Cho^{*d,e}, Jeong F. Kim^{*c,f}, Kangwon Lee^{**a,b}

^a Department of Applied Bioengineering, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, 08826, Republic of Korea

^b Research Institute for Convergence Science, Seoul National University, Suwon-si, Gyeonggi-do, Republic of Korea

^c Department of Energy and Chemical Engineering, Incheon National University, Incheon, Republic of Korea

^d Green Carbon Research Center, Chemical and Process Technology Division, Korea Research Institute of Chemical Technology, Daejeon, 34114, Republic of Korea

^e Advanced Materials and Chemical Engineering, University of Science and Technology, Daejeon, 34113, Republic of Korea

^f Innovation Center for Chemical Engineering, Incheon National University, Incheon, Republic of Korea

* Corresponding author **Dr. Young Hoon Cho**. Green Carbon Research Center, Chemical & Process Technology Division, Korea Institute of Chemical Technology (KRICT), 141 Gajeong-ro, Yuseong-gu, Daejeon, 34114, Republic of Korea.

* Corresponding author **Prof. Jeong F. Kim**. Department of Energy and Chemical Engineering, Incheon National University, Incheon, Republic of Korea.

** Corresponding author **Prof. Kangwon Lee**. Department of Applied Bioengineering, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, 08826, Republic of Korea.

Email Address: Prof. Kangwon Lee: kangwonlee@snu.ac.kr; Prof. Jeong F. Kim: JeongKim@inu.ac.kr; Dr. Young Hoon Cho: yhcho@kRICT.re.kr

34 **Abstract**

35 Extracorporeal membrane oxygenation (ECMO) is a technique that delivers gas
36 exchange to cardiopulmonary surgery patients. Membrane oxygenation failure may
37 result in serious health problems for patients due to ECMO membrane wetting and
38 surface fouling problems. Thus, in this work, the superhydrophobic membrane is
39 designed to improve the resistance to wetting and long-term fouling of the ECMO
40 membrane. The hydrophobic biocompatible polycaprolactone (PCL) was used to
41 fabricate an electrospun nanofiber membrane. Polydimethylsiloxane (PDMS) was dip-
42 coated on the PCL electrospun membrane to enhance the membrane hydrophobicity,
43 which lifts the water contact angle from 136 to 160 degrees. The PDMS90 membrane
44 shows low protein adsorption under 10 mg/mL BSA incubation, inhibiting the platelet
45 activation and intensifying long-term antifouling of the membrane. The lab-scale blood
46 oxygenation results indicate that the developed membrane is competitive with the
47 commercial polypropylene (PP) and lab-made polymethyl pentene (PMP) membranes.
48 In conclusion, the conducted experiments verify that the developed membrane has the
49 potential to be applied to the ECMO membrane.

50
51 **Keywords:** artificial lung, blood oxygenation membrane, ECMO membrane,
52 superhydrophobic membrane, poly(ϵ -caprolactone) (PCL), polydimethylsiloxane
53 (PDMS)

54 **1. Introduction**

55 With the advent of Coronavirus disease (COVID-19) [1][2], researchers have attracted
56 attention to Cardiopulmonary bypass (CPB) [3], also named as Artificial lung (AL).
57 Extracorporeal membrane oxygenation (ECMO) has developed together with such interest.
58 ECMO plays a crucial role in providing respiration assistance to severe respiratory patients by
59 assisting the gas exchange from outside of the body during heart surgery. The oxygenator is
60 the main component of the ECMO machine. Membrane oxygenators are used to oxygenate
61 blood by indirect contact between venous blood and oxygen, and the differential partial
62 pressure exchanges oxygen and carbon dioxide [4].

63 In recent years, the ECMO market has been driven by dense poly-4-methyl pentene (PMP) and
64 porous polypropylene (PP) membranes [5]. ECMO membrane is divided into dense membranes
65 and porous membranes. Dense membranes provide gas exchange by material intrinsic gas

66 solubility and diffusivity [6]. Porous membranes, on the other hand, deliver gas through the
67 pores in the membrane. Hence, the pore distribution and aperture size affect the porous
68 membrane oxygenation capacity [7] and lifespan [8]. Several existing methods for producing
69 ECMO membrane substrate are phase inversion [9][10], 3D printing [11], and spin coating
70 with initiated chemical vapor deposition [12]. Meanwhile, electrospinning can produce a
71 porous membrane, and the fiber diameter and the number of layers may affect the membrane
72 pore size [13][13][15][16][17]. Therefore, electrospun membrane with smaller fiber diameter
73 and denser layers has a potential to be exploited in the gas exchange of ECMO membranes.

74 Although the hydrophobic porous membrane has better blood oxygenation efficiency, blood
75 tends to coagulate in the pores by capillary effect and leads to a serious plasma leakage to the
76 membrane. Once the membrane is wet, the oxygenation efficiency decreases and potentially
77 endangers the patient's life. For this concern, the membrane substrate must be hydrophobic to
78 avoid wetting and prevent plasma leakage during blood oxygenation. However, an ECMO
79 machine requires a large surface area of the blood-contacting membrane for adequate gas
80 exchange, which brings concern to membrane hemocompatibility [18]. As the hydrophobic
81 surface is susceptible to protein foulants and the hydrophobic interactions act with the blood
82 components (such as protein, platelet, and cells) [19][19][20], the hazardous compounds might
83 release and activate the blood immune system after the membrane directly contacts the blood
84 [22]. Thus, the long-term operation challenges of membrane oxygenators are
85 hemocompatibility and antifouling properties [5].


86 Antifouling studies mainly aim to reduce the formation of thrombosis by inhibiting the
87 activation and aggregation of the platelet. Since the leading causes of thrombosis are protein
88 adsorption and cell adhesion on the surface [23][24], hydrophilic [25] and superhydrophobic
89 modifications [26] are employed to improve the surface hemocompatibility and subsequently
90 elevate the surface antifouling property.

91 The utilization of hydrophilic coating layers is the common surface modification method that
92 can inhibit blood clotting. Nitric oxide (NO) [26] and heparin [28] coating layers have been
93 demonstrated to suppress blood coagulation cascades, and phosphorylcholine (PC) [29] coating
94 has been found to reduce thrombosis. The poly (2-methoxyethyl acrylate) (PMEA) [30]
95 covering has been proven to diminish platelet adherence. However, the long-term wetting of
96 hydrophilic coating layers may limit ECMO performance and lifespan with unforeseen
97 biofouling, particularly for porous membranes [31]. Hence, the hydrophilic coating layer might
98 be difficult to balance between hemocompatibility and long-term antifouling.

99 To overcome membrane long-term fouling, superhydrophobic surface modifications have also
100 been investigated for blood-contacting medical equipment and healthcare devices [32][33].
101 Membrane superhydrophobicity could be improved by reducing the effective area, which can
102 also improve the surface hemocompatibility of the membrane [25]. The followings are the
103 several methods to improve superhydrophobicity: nanoparticle coating [34], plasma treatment
104 [35], chemical vapor deposition [36], vapor-induced phase separation [37], and electrospinning
105 [38]. The reported superhydrophobic modification demonstrates impressive wetting resistance,
106 protein fouling prevention, and antifouling in various gas-liquid contacting and biomedical
107 membrane applications.

108 In this sense, polycaprolactone (PCL) can be a good option for producing ECMO membranes
109 since it is a semi-crystalline hydrophobic polymer [39][40] with good hemocompatibility [41].
110 As an FDA- approved material [42], PCL has also been used in medical applications such as
111 surgical sutures [43], blood vessel grafts [44][45], and tissue regeneration scaffolds [46].
112 However, hemocompatible PCL electrospun membrane is less durable and not strong enough
113 to face long-term ECMO challenges, such as plasma leakage and antifouling. Accordingly,
114 superhydrophobic modification, such as PDMS coating, is introduced to improve the PCL
115 electrospun membrane property for the aforementioned ECMO challenges. PDMS, an FDA-
116 approved hydrophobic polymer [47], is advantageous because it can provide
117 superhydrophobicity to the membrane surface by simple modification [48][49][50][51].

118 In this work, a novel superhydrophobic ECMO membrane is created by PDMS dip-coating on
119 a hydrophobic PCL electrospun membrane substrate to improve the hemocompatibility and gas
120 transfer rate in long-term extracorporeal membrane oxygenation. The gradient PCL
121 electrospun membrane was fabricated with different concentrations to provide a hydrophobic
122 porous substrate. The PDMS solution is then diluted in hexane and dip-coated on the membrane
123 surface throughout various periods. The hemocompatibility of PDMS-coated PCL electrospun
124 membranes was characterized by hemolysis, blood clotting index, protein adsorption, cell
125 cytotoxicity, platelet adhesion, and long-term antifouling tests. In addition, sheep blood was
126 applied to simulate the blood oxygenation of the membranes. Figure 1 depicts the overall
127 manufacturing process of the PDMS-coated PCL electrospun membrane and the oxygenation
128 simulation of the membrane.



129

130 **Figure 1.** Schematic illustration of the preparation of the PDMS-coated PCL electrospun membrane for
 131 artificial oxygenation.

132

133 2. Experimental Section

134 2.1 Materials

135 Polycaprolactone (PCL) ($M_w=80,000$), Acetic acid (AA) ($\geq 99\%$), N, N-
 136 Dimethylformamide (DMF) (99.8%), PP membrane, PMP raw material and bovine
 137 serum albumin (BSA) were purchased from Sigma Aldrich. Sylgard 184 A, B (PDMS
 138 prepolymer, curing agent) were purchased from Sewang Hitech Silicone. Chloroform
 139 (CF) (99.8%), Formic acid (FA) (99.0%), n-Hexane (96.0%) were purchased from
 140 Samchun pure chemical CO., LTD. Human umbilical vein endothelial cells
 141 (HUVECs) and culture medium (EBM-2 EGM-2 Bulletkit) were purchased from
 142 Lonza. Sheep blood defibrinated and citrated were purchased from KisanBio Inc.

143

144 2.2 Gradient nanofiber by electrospinning

145 Electrospun gradient PCL membrane were prepared with different solvents and weight
 146 ratios. The first finer layer was prepared by dissolving 9 wt% of PCL in Formic acid
 147 (FA)/ Acetic acid (AA) 7/3 (v/v) solution. The solution was mixed overnight at
 148 room temperature. Then the solution was electrospun for 10 hours into nanofibers
 149 at room temperature with a voltage of 17 kV, pump speed of 0.2 mL/h, and a 23 cm
 150 distance between the needle tip and the aluminum foil-covered rotating drum

151 collector. The second denser layer was prepared by dissolving 11 wt% PCL in
152 Chloroform (CF)/ N, N-Dimethylformamide (DMF) 8/2 (v/v) solution. After
153 overnight mixing, the solution was electrospun for 27 hours into nanofibers at room
154 temperature with a voltage of 15 kV, pump speed of 1 mL/h, and a 23 cm distance
155 between the needle tip and the aluminum foil-covered rotating drum collector. The
156 third layer had the same experiment setting as the first layer. The final membrane
157 was vacuum dried overnight to remove the residual solvents and to be ready for the
158 later process.

159

160 **2.3 Polydimethylsiloxane (PDMS) modification**

161 Polydimethylsiloxane (PDMS)-modified PCL membranes were prepared by dip-
162 coating method. 1 wt% (w/w) of PDMS solution (prepolymer: curing agent kit w/w
163 10: 1) was dissolved in n-hexane. The solution was light avoiding-stirred with a
164 magnetic rod for 30min at room temperature. Then the PCL electrospun membranes
165 were immersed in PDMS/n-hexane solution with varying periods (30 min, 60 min, 90
166 min) at room temperature. After that, the coated membranes were dried overnight
167 in a vacuum oven at 40 °C. The obtained membranes are denoted as PDMS30,
168 PDMS60, PDMS90, respectively.

169

170 **2.4 Characterization of membrane**

171 Membrane morphologies and chemical compositions were characterized with FE-
172 SEM and Silicon Drift Detector EDS (JSM-7800F Prime, JEOL Ltd, Japan) at 5 kV
173 and 15 kV, respectively. A prior platinum layer was coated on the membrane surface
174 before SEM scanning by Sputter Coater (Cressington 108 auto, Watford, UK). ATR -
175 FTIR measurements were proceeded by TENSOR 27 (Bruker, Germany) ATR -
176 FTIR spectrometer at 25 °C. Sample membranes were properly vacuum dried and
177 direct measured under the spectra of 64 scans with a resolution of 2 cm^{-1} . Membrane
178 surface roughness was investigated by Atomic Force Microscope (Park NX10, Park
179 systems, Korea) over a scan area of $10 \times 10 \mu m^2$. The mechanical property of the
180 membranes was conducted following the ASTM standard using a test window
181 frame to hold the $1 \times 4 cm^2$ membrane. After loading the sample on the Universal
182 Testing Machine (Instron 5543, Instron Corp, MA, USA), the vertical ribs were cut
183 just before the start of the tensile test. Membrane tensile strength was tested with

184 a 100 *N* load cell and a 5 *mm/min* strain rate. The membrane surface contact angle
185 of water, Ethylene Glycol and blood was measured by contact angle analyzer
186 (Phoenix 300, SEO Co., Korea) with 2 μL of Deionized (DI) water and Ethylene
187 Glycol, and 4 μL of citrated sheep blood (KisanBio Ltd., Seoul, South Korea). The
188 average membrane pore size was examined by gas-liquid porometers
189 (POROLUX™ 1000, Porometer Ltd, Belgium). The membrane liquid entry
190 pressure (LEP) was determined after every 30 minutes from applying rising pressure to the
191 membrane with 0.5 bar. The membrane was fixed under the water by Amicon® cell for 24 hours
192 before testing. The membrane was immersed in water for 24 hours before the LEP test. The LEP
193 data was recorded at the first water drop fell. Membrane air permeance was investigated
194 by the capillary flow porometer (model CFP-1500-AEL, Porous Materials Inc, NY,
195 USA). The gas was supplied with 1 *bar* pressure to enter the membrane with a 1.8
196 *cm* diameter filter holder. Air permeance was denoted as gas permeation unit
197 (GPU), where $1 \text{ GPU} = 1 \times 10^{-6} \times (\text{cm}^3(\text{STP})/\text{cm}^2 \cdot \text{cmHg} \cdot \text{sec})$. The thickness of membranes was
198 measured by a digital micrometer (Coolant Proof IP65, Mitutoyo, USA).

199

200 **2.5 Membrane Blood Oxygenation**

201 The blood oxygenation test was measured using Amicon® Stirred Cells under 36 °C.
202 All the membrane samples were punched into a circular-shaped membrane with a 4.25
203 *cm* diameter and installed in the Amicon® Stirred Cells for blood oxygenation tests.
204 Defibrinated sheep blood (50 *mL*) was poured onto the top of the test membrane
205 and stirred by a dangled magnetic rod at 200 *rpm* for deoxygenating blood and 400
206 *rpm* for the oxygenation test, respectively. The circulated gases flowed underneath the
207 membrane by the tube connection between Amicon® Stirred Cells and the gas tanks.
208 After loading the sterilized membrane on the cell, the deoxygenation process took 6
209 hours of nitrogen gas flowing at a 45 *cc/min* flow rate and carbon dioxide gas flowing
210 at 4.5 *cc/min*. When the oxygen level was lower than 40 *mmHg* (measured by i-Smart
211 300 VET Blood Gas Analyser, i-SENS Inc., South Korea), oxygen gas was connected
212 to the cell, and started the oxygenation test at a 50 *cc/min* flow rate. The membrane
213 blood oxygenation property was simulated by the Amicon® cell (Figure S4). The dangling
214 rotated magnet inside the Amicon® cell mixed the sheep blood to balance the sheep blood
215 oxygen level inside the Amicon® cell for getting reliable data. The variations in blood
216 oxygen level were recorded every 5 minutes until the oxygen level went beyond 200

217 *mmHg*. The CO_2/O_2 exchange rate calculation was based on the margins of blood
 218 oxygen over a settled period. The oxygen transfer rate ($mL O_2/m^2/min$) was
 219 calculated by dividing the total O_2 transfer quantity ($mL O_2$) by the blood-
 220 contacting area of the membrane (m^2). The total O_2 transfer quantity is the sum of
 221 total O_2 bound to hemoglobin (hbO_2) and dissolved O_2 in plasma (plO_2).

$$222 \text{ Oxygen transfer rate (mL } O_2/m^2/min) = \frac{d(sO_2+bO_2)}{dt \cdot A} \quad (1)$$

223 Where sO_2 is the oxygen dissolving volume (mL) in blood, bO_2 is the oxygen volume
 224 (mL) bound to hemoglobin, t is the time (min), and A is the tested membrane area
 225 (m^2).

226

227 **2.6 Protein adsorption**

228 The static membrane protein adsorption test was implemented with a petri dish.
 229 The $2 \times 2 \text{ cm}^2$ membrane was first immersed in PBS and equilibrium under UV
 230 sterilization for 3 hours. After discarding the PBS, 2 mL of bovine serum albumin
 231 (BSA) (Sigma-Aldrich, USA) with 10 mg/mL concentration in PBS was prepared
 232 and submerged on the membrane surface, followed by incubating for 3/6/9 hours
 233 respectively at 37 °C with a 5% CO_2 incubator. After aspirating the BSA solution
 234 from the well, the membrane was rinsed gently with PBS three times to wash out
 235 non-absorbed protein. Then the membrane was immersed in 2 wt% aqueous
 236 sodium dodecyl sulfate (SDS) solution for 1 hour in the 37 °C incubator and 1 hour
 237 with a shaking table under room temperature to remove the adsorbed protein from
 238 the membrane. The membrane protein concentration and standard curve were
 239 measured by a BCA kit. In short, 25 μL of membrane solution and 200 μL of
 240 working reagent (A: B 50:1) were pipetted into a 96-well plate. After 30 seconds of
 241 gently plate shaking, the foil-covered 96-well plate was incubated in the 37 °C
 242 incubator for 2 hours. Lastly, the protein adsorption amount of the membrane was
 243 measured by the microplate reader (BioTek Synergy H1 Hybride Multi-mode
 244 reader, Agilent technologies, United States) with 562 nm absorbance.

245

246 **2.7 Platelet adhesion**

247 Firstly, citrated sheep blood (KisanBio Ltd., Seoul, South Korea) was centrifuged
 248 at 3500 rpm for 15 min , and the platelet rich plasma (PRP) suspension was extracted

249 and measured using the Countess II (Invitrogen) which showed 7×10^7 U/mL. UV
250 sterilized 1×1 cm² membrane was placed in the petri dishes, and PBS solution was
251 added to equilibrate membrane surface at room temperature for 2 hours and
252 incubated for 30 min. After discarding the PBS solution, 100 μ L PRP was added onto
253 each side of the membrane surfaces and incubated in the 37 °C humidified incubator
254 with 5% CO₂ flow for 2 hours. Then the sample was rinsed with PBS solution 3 times
255 to remove the non-adherent platelets. The membrane was immersed into 2.5 wt%
256 glutaraldehyde aqueous solution at 4 °C for 24 hours to immobilize the platelets on
257 the sample surface. Subsequently, the membrane was rinsed three times by PBS
258 and dehydrated by a graded ethanol (v/v) from PBS (0%, 10%, 25%, 50%, 75%,
259 100%) with 10 min for each step. Lastly, the platelets-adhered surface was observed
260 by SEM.

261

262 **2.8 Hemolysis rate**

263 All the samples were cut into 1×1 cm² and immersed in 1.5 mL PBS and were
264 incubated in the 37 °C humidified incubator with 5% CO₂ flow for 2 hours. After
265 incubation, 30 μ L of citrated sheep blood (KisanBio Ltd., Seoul, South Korea) were
266 added into the microtube with further 2 hours of incubation. Afterward, the microtubes
267 were centrifuged at 2500 rpm for 30 minutes. The supernatant was extracted into a
268 96-well plate with 200 μ L per well and measured by a microplate reader (BioTek
269 Synergy H1 Hybride Multimode reader, Agilent technologies, United States) under
270 the 545 nm. The positive control was prepared by dissolving 30 μ L of citrated sheep
271 blood in 1.5 mL of deionized water, while the negative control was prepared by adding
272 30 μ L of blood to a PBS solution. The calculation of hemolysis rate (HR) was
273 calculated as follows:

$$274 \quad HR = [(A_{sample} - A_{negative}) / (A_{positive} - A_{negative})] \times 100\% \quad (2)$$

275

276 **2.9 Blood clotting index**

277 The blood clotting test was operated with citrated sheep blood (KisanBio Ltd.,
278 Seoul, South Korea). The 5×5 mm² samples were immersed with deionized water
279 within the 2 mL microtube for 1 hour incubation. After discarding the deionized water,
280 60 μ L of blood and 4.5 μ L of 0.2 M calcium chloride aqueous solution were pipetted

281 to contact the surface of the membrane and incubated for 5 min. Subsequently, 1.5
 282 mL of deionized water was dropped into the microtube without directly touching the
 283 membrane surface. 200 μL of the supernatant was tested within a 96-well plate under
 284 the 540 nm by the microplate reader (BioTek Synergy H1 Hybride Multi-mode reader,
 285 Agilent technologies, United States). The negative control group was prepared by
 286 dissolving 60 μL of blood in 1.5 mL of the deionized water. The process has been
 287 repeated three times to collect the average data. The blood clotting index (BCI)
 288 was calculated by:

$$289 \quad BCI (\%) = [(A_{sample})/(A_{negative})] \times 100\% \quad (3)$$

290

291 **2.10 Cytotoxicity**

292 Human Umbilical Vein Endothelial Cells (HUVEC) were selected to be the model cell
 293 to detect the membrane cytotoxicities (PCL, PDM90, PP, and PMP membranes) by
 294 direct contact Cell Counting Kit-8 (CCK-8) assay. The samples for CCK-8
 295 cytotoxicity test were prepared with $5 \times 5 \text{ mm}^2$. After 90 min of UV sterilization, the
 296 samples were equilibrated with PBS 3 times (1 hour/time). The HUVEC cells were
 297 pre-seeded into a 96-well plate with a density of 1×10^4 cells per well with overnight
 298 incubation. Before the input of membrane samples, the culture medium was replaced
 299 by the non-antibiotic fresh medium (EBM-2, Lonza). The sample-immersed plates
 300 were cultured at 37 °C with 5% CO₂ for 24 h, 48 h, and 72 h, respectively. The non-
 301 sample-immersion control was performed as a blank control for each time point. For
 302 each measurement, the samples and culture medium were carefully discarded, and
 303 10% CCK-8 solution with fresh medium (110 μL) was pipetted into each well,
 304 followed by 45 min incubation. The absorbance results of each well were determined
 305 by the microplate reader (BioTek Synergy H1 Hybride Multi-mode reader, Agilent
 306 technologies, United States) at 450 nm. The cytotoxicity value was indicated as cell
 307 viability (%). The cell viability was calculated by:

$$308 \quad Cell \text{ Viability } (\%) = [(A_{sample}) - (A_{blank})]/(A_{Control}) - (A_{blank})] \times 100\% \quad (4)$$

309

310 **2.11 Statistical Analysis**

311 Statistical analyses were performed by ImageJ (NIH, USA) and one-way ANOVA in
 312 Prism (GraphPad, San Diego, CA, USA). The *p*-values were represented with asterisks (*)

313 are as follows: $ns > 0.05$; $*p < 0.05$; $**p < 0.01$; $***p < 0.001$; $****p < 0.0001$.

314

315 **3. Results and Discussion**

316 **3.1 Membrane morphology and characteristics**

317 A blood oxygenation membrane aims to provide sufficient oxygen to the blood. The
318 commercial products and the existing research of ECMO membranes focus on reducing
319 the pore sizes (about 30-40 nm diameter) to balance the prevention of blood leakage and
320 the pass of adequate oxygenation [52]. The leakage prevention of the membrane can also
321 be achieved by low surface energy with superhydrophobicity while maintaining sufficient
322 membrane pore sizes. Herein, gradient electrospun nanofiber was prepared as a
323 macroporous membrane. Figure 2a shows that the gradient PCL electrospun membrane
324 comprises two kinds of fiber diameters. The surface layers were fabricated by 9 wt% PCL
325 with 112 nm of the mean fiber diameter, which aimed to reduce the membrane mean pore
326 sizes. On the other hand, the middle layer was fabricated by 11 wt% PCL, with a 322 nm
327 mean diameter, to provide sufficient mechanical properties.

328 The surface SEM images of the PCL electrospun membrane with different PDMS coating
329 periods (0 min, 30 min, 60 min, 90 min) are shown in Figure 2b. The existence of PDMS
330 after PDMS dip-coating could also be confirmed by EDS analysis (Figure S1), showing
331 that Si was detected on the membrane after PDMS coating. The average membrane
332 thickness of commercial PP and lab-made PMP is 0.133 mm and 0.044 mm . PCL, PDMS30,
333 PDMS60, and PDMS90 have average membrane thicknesses of 0.199 mm , 0.203 mm ,
334 0.207 mm , and 0.210 mm , respectively (Figure S5). The coating layer gradually cross-
335 linked on the surface by the increasing coating time from 0 min to 90 min. It is also
336 presented in Figures 2c and 2d that the root mean square surface roughness decreased from
337 0.5038 μm of 0 min coating membrane to 0.1624 μm of 90 min coating samples through
338 AFM scanning. The commercial 0.6 μm polypropylene (PP) Prefilter membrane (Sigma-
339 Aldrich, USA) was purchased to compare the sample properties with those of commercial
340 polymers. Since polymethyl pentene (PMP) did not have a commercial flat film, the lab-
341 made PMP membrane was developed, and the process details are included in the support
342 information. The SEM image of the PMP film and the pore size analysis are listed in the
343 support information (Figure S2).


344 The transmittance spectra of functional groups differences of pristine PCL electrospun
345 membrane and PDMS-treated membrane were acquired through the ATR FTIR

346 spectrometer (Figure 2e). PCL transmittance showed asymmetric and symmetric stretching
347 vibration of the $-\text{CH}_2$ bond at 2944 and 2866 cm^{-1} . The strong carbonyl ($-\text{C}=\text{O}$) stretching band
348 of PCL was represented at around 1726 cm^{-1} . 1295 cm^{-1} indicated C-O and C-C stretching of
349 PCL, and asymmetric and symmetric C-O-C stretching bonds were denoted at 1240 and 1171
350 cm^{-1} of PCL transmittance. The PDMS-coated membrane showed an intense peak at around
351 800 cm^{-1} representing the $-\text{CH}_3$ rocking in the Si- CH_3 bond. Si-O-Si bonds of PDMS were
352 shown at 1089 and 1048 cm^{-1} . At the 1240 cm^{-1} band, the PDMS-coated membranes presented
353 more prominent peaks demonstrating the $-\text{CH}_3$ symmetric bending in Si- CH_3 . The peak in
354 2944 cm^{-1} also represented the C-H stretching in the CH_3 group. The spectra proved that after
355 dip-coating, PDMS was successfully cross-linked on the surface of the membrane.


356 Tensile strength is a critical property of materials. Figure 3a and 3b illustrate tensile stress
357 and strain comparisons, as well as Young's modulus values for different membranes. As
358 the PDMS-coating period was increased, the strain value decreased from 79% of the
359 pristine PCL electrospun membrane to 47% of the PDMS90 membrane. The lower
360 deformation potential reduced the unintentional change in membrane pore size during
361 membrane oxygenation. Meanwhile, the stress value increased from 11 MPa of PCL to 13
362 MPa of PDMS90, indicating that prolonging the PDMS coating duration enhanced the
363 membrane deformation resistance. Young's modulus improved steadily from 15 MPa of
364 PCL to 25 MPa of PDMS90. The stiffness of the membrane was increased after PDMS
365 dip-coating. Surface roughness and surface chemistry both affect surface hydrophobicity
366 [53]. Based on the water contact angle results (Figure 3c) and the surface roughness results
367 (Figures 2c and 2d), PDMS coating improves the hydrophobicity of the membrane due to
368 the siloxane in the PDMS, from 135.7 degrees of PCL electrospun membrane to 160.2
369 degree of PDMS60. The decreased surface roughness from 0.29 μm of PDMS60 to 0.16
370 μm of PDMS90 decreased the water contact angle from 160.2 degrees to 153.3 degrees.

371 At the same time, the blood contact angle of different membranes was measured.
372 According to Figure 3d, as the period of PDMS coating increased, the blood contact angle
373 increased from 121 degrees of PCL to 141 degrees of PDMS90. The surface energies of the
374 membrane were measured by water and ethylene glycol contact angles and computed by
375 the Owens, Wendt, Rabel and Kaelble (OWRK) method. The results are shown in Table
376 1. As can be observed, the PDMS coating significantly lowered the surface energy of the
377 membranes. Surface energy was correlated to surface roughness and material chemistry [53].
378 The intrinsic chemical characteristics include atomic composition, polarizability, and

379 crystallinity. Because of the existence of low surface energy elastomer silicone and the low
 380 intermolecular interactions between the methyl group, as well as the flexibility of the
 381 siloxane backbone, PDMS shows a low surface energy [54] as it is widely known.
 382 Therefore, PDMS coating significantly reduced membrane surface energy from over 250
 383 mN/m before coating to lower than 10 mN/m after coating.



384
 385 **Figure 2.** SEM images and fiber diameter analysis of (a) 9 wt% and 11 wt% gradients PCL electrospun
 386 membrane; (b) SEM images and (c) AFM images of membrane surface morphologies with PDMS dip-
 387 coating for 0 min (PCL), 30 min (PDMS30), 60 min (PDMS60) and 90 min (PDMS90); (d) the surface
 388 roughness analysis; and (e) ATR-FTIR examination of PCL, PDMS30, PDMS60, and PDMS90
 389 membranes.



390
 391 **Figure 3.** (a) The mechanical properties and (b) Young's modulus of PCL, PDMS30, PDMS60, and
 392 PDMS90 membranes. (c) Water contact angle and (d) blood contact angle of PCL, PDMS30, PDMS60,
 393 and PDMS90 membranes.

394

Membranes	Contact angle (degree)		Surface energy (mN/m)
	Water	Ethylene glycol	
PCL	135.7	28.88	251.2
PDMS30	146.3	125.67	6.70
PDMS60	160.2	139.82	3.62
PDMS90	153.3	130.97	6.36

395

396 **Table 1.** The comparison of contact angles and surface energy of different membranes.

397

398 3.2 Hemocompatibility of the membrane

399 3.2.1 Hemolysis assay

400 Since the ECMO membrane comes into direct touch with the patient's blood, membrane
 401 hemocompatibility must be investigated. Hemolysis appears when blood directly contacts
 402 the foreign elements that may activate the complement system and results in inflammation.

403 The hemolysis ratio may reflect a material's blood compatibility. The in vitro hemolysis
404 assay showed that all samples, including commercial PP and lab-made PMP, had
405 average hemolysis ratios of less than 0.6%. (Figure 4a). The results show that all the
406 samples are comparably safe for in vitro hemolysis tests, in accordance with the American
407 Society for Testing and Materials Standard (ASTM F756-2008). PCL, PDMS30, and
408 PDMS60 had higher hemolysis ratios than commercial PP and lab-made PMP, whereas
409 commercial PP and lab-made PMP had hemolysis rates less than 0.4%. PDMS90 had an
410 excellent hemolysis ratio of 0.22% on average, which was lower than lab-made PMP
411 (0.24%). Among the tested samples, the PDMS90 membrane showed the best
412 hemocompatible capability, suggesting that the hemocompatible PDMS90 has the
413 potential for ECMO application.

414

415 **3.2.2 Blood Clotting Index**

416 The blood clotting index (BCI) assesses clotting formation capacity, which reveals the
417 percentage of red blood cells that are not caught by clots. A lower BCI level indicates
418 that the materials are significantly prone to clotting. According to figure 4b, the
419 average BCI value for pristine PCL electrospun membrane was lower than 90%. The
420 BCI tended to grow as the PDMS-coating duration increases. PDMS90 had a BCI
421 value of more than 95%, which was comparable to the commercial PP membrane
422 (96.6%). Since PDMS90 had a lower clotting potential, platelet plugs and fibrin clots were
423 less likely to form on the membrane. Meanwhile, the oxygenation tunnel might work better
424 for a longer period with less clogging. The results suggest that PDMS90 could be
425 employed as an ECMO membrane with minimal clotting potential.

426

427 **3.2.3 Protein adsorption**

428 After the blood directly contacts an artificial surface, protein adsorption appears in a matter
429 of seconds as a forepart reaction. Proteins have a significantly smaller size than cells,
430 which causes them to adhere to the microscopic structure more than cells. When a large
431 number of proteins are bound to the surface, the artificial surface may activate blood cells
432 and cause thrombosis [55]. Meanwhile, the adhesive proteins have a proclivity for cell
433 attraction, which will eventually block the oxygenation tunnel and limit the ECMO
434 membrane's oxygenation rate [24]. The difficulty in modifying ECMO membrane surfaces is
435 lowering protein adhesion to prevent further thrombosis and increase service life. In figure

436 4c, all membrane samples were examined for 3, 6, and 9 hours with a high concentration of
437 10 mg/mL bovine serum albumin. At 3 hours of incubation, PDMS90 ($0.85 \mu\text{g}/\text{cm}^2$)
438 revealed less than $1 \mu\text{g}/\text{cm}^2$, indicating effective protein adsorption avoidance. Protein
439 adsorption of the membranes fell considerably after PDMS coating, from over $100 \mu\text{g}/\text{cm}^2$
440 of pristine PCL electrospun membrane to less than $10 \mu\text{g}/\text{cm}^2$ of PDMS-coated membrane
441 at 9 hours (PDMS30: $6.31 \mu\text{g}/\text{cm}^2$, PDMS60: $4.99 \mu\text{g}/\text{cm}^2$, PDMS90: $3.87 \mu\text{g}/\text{cm}^2$). When
442 compared to commercial PP and lab-made PMP membranes, the PDMS-modified
443 membrane showed a significant reduction in protein adsorption, with less than half of
444 PP and PMP after 9 hours of incubation. Figure 5 reviews various membranes applied to
445 ECMO machines and antifouling bio-interfaces. It presents that this work (PDMS90) has a low
446 protein adsorption amount under the incubation of relatively high BSA concentration
447 ($10 \text{ mg}/\text{mL}$), which stands out from other works. The membranes have been repeatedly tested
448 with $1 \text{ mg}/\text{mL}$ of BSA concentration for 3, 6, and 9 hours (Figure S6). It shows that PDMS90
449 possesses lower than $1.5 \mu\text{g}/\text{cm}^2$ protein adsorption after 9 hours of incubation with $1 \text{ mg}/\text{mL}$
450 BSA solution. The details of figure 5 are listed in table S1. The results demonstrate that the
451 superhydrophobicity and the relative roughness of the PDMS-coated membrane surface
452 inhibited protein adhesion, and the low protein adsorption membrane has the potential to apply
453 to the ECMO membrane.

454

455 3.2.4 Cytotoxicity


456 Because the ECMO membrane is in direct touch with the blood extracted from the venous
457 vessels, the blood will return to the patient's body via the arterial channel. The membrane's
458 safety is also critical. According to the biological assessment of medical devices
459 (ISO10993-5), Cell Counting Kit-8 (CCK-8) was used to examine the in vitro cytotoxicity
460 of the ECMO membrane using Human Umbilical Vein Endothelial Cells (HUVEC).
461 The cytotoxic potential of materials such as PCL, PDMS90, commercial PP, and lab-
462 made PMP was investigated (Figure 4d). The cell viability of several samples was tested
463 for 24 hours, 48 hours, and 96 hours in the non-antibiotic-free medium. Based on the
464 conventional quantitative level (ISO 10993-5:2009), at 24 hours, PCL had 75.8% cell
465 viability, lab-made PMP had 80.7%, and PDMS90 had 84.9% viability. PCL, PMP, and
466 PDMS90 membranes were defined as level 1 cytotoxicity after 24 hours. Commercial PP
467 (71.5%) had the lowest cell viability and was defined as level 2 cytotoxicity at 24 hours.
468 Only PDMS90 retained more than 80% cell viability after 48 hours, followed by 78.86% for

469 PMP, 69.08% for PP, and 66.3% for PCL. At 48 hours, PDMS90 and PMP still showed
470 level 1 cytotoxicity, but PP and PCL demonstrated level 2 cytotoxicity. PMP (75%)
471 presented the best cytotoxicity after 72 hours with level 1 cytotoxicity. At 72 hours,
472 PDMS90 (59.7%) demonstrated level 2 cytotoxicity, while PCL (40.94%) and PP
473 (31.38%) showed level 3 cytotoxicity. The results suggest that PDMS90 might be used as
474 a medical device, but it may require further treatment to lessen the cytotoxic potential in
475 the long-term application.

476

477 **3.2.5 Platelet adhesion**

478 Platelets are anucleate blood cells that might participate in inflammation during extracorporeal
479 membrane oxygenation [26]. When the membrane encounters blood, proteins (albumins
480 and globulins) tend to bind to the membrane surface. After that, fibrinogens gradually replace
481 small proteins and attach to the membrane surface due to the Vroman effect [56]. Platelets
482 tend to aggregate in the presence of fibrinogens. Subsequently, the platelet will be activated
483 and spread the pseudopodia. Furthermore, the extent of platelet activation on ECMO might
484 improve with increasing blood contact time, resulting in a membrane with a low
485 oxygenation efficiency. For the platelet adhesion test, extracted sheep platelets were
486 utilized — platelet diameters in sheep range from 3.2 to 5.4 $fL(\mu m^3)$ [57]. Figure 4e
487 depicts the platelet formed on various membrane surfaces. The platelet on the pristine
488 PCL electrospun membrane surface had been activated with multiple pseudopodia.
489 Through SEM pictures, the platelet appeared reductive activation as the PDMS coating
490 time increased. A platelet on the surface of a commercial PP membrane was severely
491 activated. In contrast, a platelet on the surface of a lab-made PMP membrane was hardly
492 activated, which was similar to the PDMS90 surface platelet. The platelet adhesion is also
493 related to material surface roughness [58]. PDMS dip-coating reduced the surface
494 roughness (Figure 2d), which conduce to less platelet adhesion on the membrane surface.
495 Hence, the surface was modified into superhydrophobic with relatively lower surface
496 roughness and minimal protein adsorption, PDMS coating reduced platelet activation and
497 could potentially extend service life in ECMO applications.



498

499 **Figure 4.** Hemocompatibility evaluation of PCL, PDMS30, PDMS60, PDMS90, commercial PP, and

500 lab-made PMP: (a) hemolysis ratios (b) the corresponding blood clotting index values (c) protein adsorption


501 of membranes with 10 mg/mL BSA concentration at 3, 6, 9 hours respectively; (d) cytotoxicity analysis

502 of PCL, PDMS60, commercial PP, and lab-made PMP membranes by the cell viability for 24, 48, 72

503 hours respectively. (e) SEM images of surface platelet activation for PCL, PDMS30, PDMS60,

504 PDMS90, commercial PP, and lab-made PMP membranes. (Scale bar: 1 µm.)

505



506

507 **Figure 5.** The comparison of protein adsorption of various membranes applied to ECMO and bio-
508 interfaces (details are listed in Figure S6 and Table S1).

509

510

511 **3.2.6 Long-term antifouling**

512 The superhydrophobicity of the ECMO membrane is designed to extend the lifetime of
513 respiratory assistance. The long-term antifouling ability of the membrane surface is also
514 crucial; by reducing cell adhesions over time, oxygenation could theoretically persist longer.

515 The membrane samples were steeped in citrated sheep blood for 28 days in this study to
516 test long-term antifouling properties. The antifouling ability of the membrane surfaces was
517 observed by SEM at 7-day intervals and photography at 28-day (Figure 6).

518 From photography, the PCL and commercial PP membranes had significant clotting on
519 the surface, as observed in the 28-day image. In contrast, the PDMS-coated membrane
520 surfaces were comparable to the fresh membrane (control). After 28 days of blood


521 interaction, the lab-made PMP membrane likewise had a clean surface. Simultaneously,
522 SEM pictures of PCL and commercial PP membrane surfaces indicated incremental
523 thrombus buildup at 28 days, the PP membrane surface accumulated activated platelets

524 from day 14, and the PCL electrospun membrane showed active platelets from day 21.
525 PDMS-coated membranes and lab-made PMP demonstrated better antifouling
526 characteristics. The increased coating duration from PDMS30 to PDMS90 delivered a

527 preferable antifouling feature to the membrane. Meanwhile, PDMS60 and PDMS90
528 exhibited similar antifouling capabilities to lab-made PMP membranes with nearly free of
529 thrombus and activated platelets. The results demonstrate that the PDMS coating

530 significantly increased the membrane's long-term anticoagulant property. The competitive
531 performance might be traced to the inert siloxane of the PDMS coating layer, which enabled
532 the membrane with low surface energy and superhydrophobicity. The superhydrophobic

533 surface collected less protein from the blood, which reduced both platelet activation and
534 erythrocyte adherence, resulting in a longer-term possibility of anticoagulation.



535

536 **Figure 6.** (Top) 28 days antifouling examination of membranes (Control: Non-blood contacted clean

537 PDMS60 membrane, PCL, PDMS30, PDMS60, PDMS90, commercial PP, and lab-made PMP);

538 (Bottom) SEM micrographs of membranes after citrated sheep blood incubation for 7, 14, 21, 28 days

539 respectively.

540

541 **3.3 Membrane Blood Oxygenation**

542 The pore size of the membrane may influence the rate of oxygenation. The mean pore
543 diameter of a commercial PP membrane (Sigma-Aldrich, USA) was $0.6\ \mu\text{m}$, and the mean
544 pore size of a lab-made PMP was $1.74\ \mu\text{m}$ (Figure S2). Meanwhile, the PCL electrospun
545 membrane had a mean flow pore diameter of $261.6\ \text{nm}$, $334.5\ \text{nm}$ for PDMS30, $276.5\ \text{nm}$ for
546 PDMS60, and $213.4\ \text{nm}$ for PDMS90, respectively (Figure 7a). Among them, the rising pore
547 size of PDMS30 was due to the capillary effect that accumulated the nanofiber clusters
548 during PDMS dip-coating. When the dry membrane was submerged in the coating
549 solution, the nanofibers of the membrane tended to aggregate owing to the cohesiveness
550 between liquid and solid [59][60]. The steady decrease in pore sizes of PDMS60 and
551 PDMS90 was linked to the enhancement of the PDMS cross-linking degree, which was
552 well-distributed across the membrane surface and reduced pore sizes [61].


553 Gas permeance is also affected by pore size and membrane interior structure. All the test
554 samples had an air permeance greater than 2.7×10^5 GPU. Whereas commercial PP had
555 1.56×10^4 GPU of air permeance, lab-made PMP had 4.27×10^2 GPU [52]. Figure 7b
556 indicates that the PDMS-coated membrane significantly lowered air permeance, and it was
557 owing to the denser interior structure. The PCL electrospun membrane had a loose internal
558 structure prior to coating, and the PDMS coating method not only assembled the surface
559 nanofiber but also congregated the fibers between various layers. Therefore, the overall air
560 permeation channel had been diminished, and the air permeance of the PDMS90 membrane
561 decreased dramatically to 2.7×10^5 GPU. However, as compared to other products [25][26],
562 these tested samples still had good air permeability.

563 The hydrophobicity of a PCL electrospun membrane was enhanced to
564 superhydrophobicity by PDMS coating. The goal of membrane superhydrophobicity was
565 to avoid blood leakage during blood oxygenation. To test the wetting stability of the
566 membrane, the membranes were pre-fixed under the water for 24 hours before applying
567 pressure. The liquid entry pressure (LEP) of a hydrophobic membrane is the pressure
568 required to pass the liquid through a membrane. According to Figure 7c, when the PDMS
569 coating duration increased, the LEP increased from $0\ \text{bar}$ of PCL to $1.625\ \text{bar}$ of
570 PDMS90. Even though the electrospun PCL membrane has over 135 degrees of water
571 contact angle, it showed $0\ \text{bar}$ after 24 hours of pre-wetting. This result could be due to the
572 free arrangement of electrospun fiber that allows the water to pass through in long-term

573 contact with water. The increasing LEP value is bounded up with the decreasing pore size,
574 the increasing thickness of the membrane, and the improving hydrophobicity by the PDMS
575 dip-coating. Consequently, the possibility of blood leakage through the membrane pores
576 was reduced as compared to the PCL electrospun membrane, and the blood oxygen
577 exchange tunnel was less likely to get clogged because of improved hydrophobicity.

578 A membrane oxygenator has gas flowing at the interior of the gas exchange hollow fiber,
579 and the blood is pumped to flow around the exterior of the hollow fibers. The O_2/CO_2
580 exchanges during the flow, and the blood is latterly led back to the patient's body after the
581 oxygenation. A dead-end system is applied to target the membrane oxygen transfer rate
582 using Amicon® cells to avoid undesired influences for testing membrane oxygenation
583 efficiency. The membrane separated the flown gas and the gently stirred blood, and the
584 O_2/CO_2 was exchanged through the membrane pores and the gas permeability of the
585 materials. The oxygen level of sheep blood was measured from under 70% in 5 minutes
586 intervals and recorded until it reached over 95%. Figure 7d and 7e compare the blood
587 oxygenation simulation efficiency of commercial PP, lab-made PMP, and PDMS-coated
588 membranes. Among the tests, commercial PP ($6.16 \text{ mL } O_2/m^2/min$) had the highest oxygen
589 exchange rate, whereas dense lab-made PMP ($3.53 \text{ mL } O_2/m^2/min$) had the lowest value.
590 Because the PCL electrospun membrane was not superhydrophobic that cannot prevent blood
591 leakage over the period, it was ineligible for the blood oxygenation simulation test. PDMS
592 had superior intrinsic oxygen and carbon dioxide gas permeability when compared to
593 commercial PP and lab-made PMP polymers [62][63]. The increasing coating duration of
594 PDMS offered a more competitive oxygenation efficiency to the membranes ($4.66 \text{ mL } O_2/m^2/min$
595 of PDMS30, $4.95 \text{ mL } O_2/m^2/min$ of PDMS60, and $5.74 \text{ mL } O_2/m^2/min$ of
596 PDMS90). The blood oxygen saturation level revealed that PP and PDMS90 met at 20
597 minutes with an 88% blood saturation level and continued to increase at the same rate from
598 20 minutes to 30 minutes until exceeding 95% of the oxygen saturation level, where the
599 normal oxygen level in a healthy lung is between 95% and 100% [64]. Figure S3 shows
600 the tested sheep blood was completely removed from the surface of the PDMS30,
601 PDMS60, and PDMS90 membranes, by gentle distilled water rinsing after the membranes
602 had completed deoxygenation and blood oxygenation tests. The clean surfaces also
603 demonstrate the PDMS-coated antifouling membranes could have promising and stable
604 blood oxygenation properties without thrombus adhesion. As a result, according to the
605 saturation level test, PDMS90 was competitive with commercial PP membranes that had

606 the same saturation speed to achieve 97% at 30 minutes during the test. The oxygenation
 607 characteristics of a PDMS-coated PCL electrospun membrane were comparable to those of
 608 commercial PP and lab-made PMP membranes. As a competitor, PDMS-coated PCL
 609 electrospun membrane has enormous blood oxygenation potential to be utilized for
 610 ECMO membranes.



611
 612 **Figure 7.** (a) Mean pore diameter distribution and corresponding (b)air permeances and (c)Liquid
 613 Entry Pressure (LEP)of PCL, PDMS30, PDMS60, and PDMS90. (d) Oxygen transfer rate and (e)
 614 oxygen saturation level of PP, PMP, PDMS30, PDMS60, PDMS90.

615

616 4. Conclusions

617 In this work, we created a PCL electrospun membrane with a PDMS dip-coated
 618 superhydrophobic surface. Two different concentration solutions (9 wt% and 11 wt%) were
 619 prepared to produce a gradient PCL electrospun membrane to form a hydrophobic porous
 620 membrane. PDMS dip-coating lifts the water contact angle from 135 degrees to 160 degrees,
 621 enhancing the membrane's long-term antifouling. The PDMS dip-coating also improves the
 622 hemocompatibility of the membrane. Under 10 mg/mL BSA concentration, the protein

623 adsorption of the membrane dramatically reduces from $118 \mu\text{g}/\text{cm}^2$ of PCL electrospun
624 membrane to $3.9 \mu\text{g}/\text{cm}^2$ of PDMS90 at 9 hours incubation. The protein adsorption of PDMS90
625 was also lower than the commercial PP and lab-made PMP membranes. Less protein adsorption
626 of the membrane surface further depresses the platelet activation and improves the long-term
627 antifouling property. PDMS dip-coated PCL electrospun membrane also shows competitive
628 blood oxygenation performance. PDMS90 meets PP at 20 min with an 88% oxygen saturation
629 level; after that, keeping the same speed as PP and reaches 97% at 30 min. Meanwhile, the gas
630 transfer rate of PDMS90 is $5.7 \text{ mL } O^2/\text{m}^2/\text{min}$, which is competitive with $6.16 \text{ mL } O^2/\text{m}^2/\text{min}$ of
631 commercial PP membrane. Compared to the most often used materials for ECMO membranes,
632 the PDMS-coated PCL electrospun membrane is comparable to the hemocompatibility of lab-
633 made PMP membranes and competitive with the blood oxygenation capability of commercial
634 PP membranes. Thus, the PDMS-coated PCL electrospun membrane exhibits superior overall
635 performance, indicating its potential for ECMO application. For the next step of developing
636 the PDMS dip-coated PCL electrospun membrane for ECMO application, the collector could
637 be adjusted to a small diameter cylinder to get the hollow-shaped tube, which could test and
638 simulate the blood flow, shear force, and pressure in the hollow tube oxygenator in the future.
639 Surface superhydrophobic modification by FDA- approved materials could also benefit various
640 blood-directly-contacting medical interfaces, such as blood vessel grafts, blood tubes, and
641 blood reservoirs.

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656 **Author statement**

657 **Zhuomin Jiang:** Conceptualization, Methodology, Data analysis, Writing-original
658 draft, Writing-review & editing. **Bao Tran Duy Nguyen:** Methodology, Data analysis.
659 **JeongHyeon Seo:** Methodology, Data analysis. **Changgi Hong:** Methodology, Data
660 curation. **Dongwoo Kim:** Methodology, Data curation. **Suhyun Ryu:** Data curation.
661 **Sohui Lee:** Data curation. **Gyubok Lee:** Data curation. **Young Hoon Cho:** Review
662 & Editing, Validation, Resources. **Jeong F. Kim:** Review & Editing, Validation,
663 Resources. **Kangwon Lee:** Supervision, Funding acquisition, Project administration.

664
665

666 **Declaration of competing interest**

667 The authors declare no conflicts of interest.

668
669

670 **Acknowledgements**

671 This work was in part supported by the Research Institute for Convergence Science,
672 Graduate School of Convergence Science and Technology and Research Institute of
673 Advanced Materials, Seoul National University. This work was supported by the Ministry
674 of Trade, Industry and Energy (20018522, 20010846). This work was supported by a grant
675 from the Korea Health Technology R&D Project through the Korea Health Industry
676 Development Institute (KHIDI), funded by the Ministry of Health and Welfare,
677 Republic of Korea (grant number: HI22C1394, HI22C1234). This work was also
678 conducted with the support of the Ministry of Science and ICT (SI2211-40, KRICT).

679
680

681 **Appendix A. Sample Appendix Section**

682 EDS analysis of PCL electrospun membrane before and after PDMS dip-coating. SEM
683 image and pore size analysis of lab-made PMP membrane. The fabrication instruction of
684 lab-made PMP membrane. Photograph of various PDMS dip-coated membranes after
685 blood oxygenation tests and the surface with a gentle distilled water rinse. The comparison
686 of various low protein adsorption membranes for ECMO and bio-interfaces.

687

688 **References**

- 689 [1] A. Vuylsteke, Ecmo in covid-19: do not blame the tool, *The Lancet* 398 (10307) (2021) 1197–
690 1199. [https://doi.org/10.1016/s0140-6736\(21\)02137-1](https://doi.org/10.1016/s0140-6736(21)02137-1)
- 691 [2] J. Badulak, M. V. Antonini, C. M. Stead, L. Shekerdemian, L. Raman, M. L. Paden, C.
692 Agerstrand, R. H. Bartlett, N. Barrett, A. Combes, R. Lorusso, T. Mueller, M. T. Ogino,
693 G. Peek, V. Pellegrino, A. A. Rabie, L. Salazar, M. Schmidt, K. Shekar, G. MacLaren,
694 D. Brodie, Extracorporeal membrane oxygenation for covid-19: Updated 2021 guidelines
695 from the extracorporeal life support organization, *ASAIO Journal* 67 (5) (2021) 485–495.
696 <https://doi.org/10.1097/mat.0000000000001422>
- 697 [3] G. Martinez, A. Vuylsteke, Extracorporeal membrane oxygenation in adults, *Continuing*
698 *Education in Anaesthesia Critical Care Pain* 12 (2) (2011) 57–61.
699 <https://doi.org/10.1093/bjaceaccp/mkr056>
- 700 [4] W. J. Federspiel, K. A. Hench, Lung, artificial: basic principles and current applications,
701 *Encyclopedia of biomaterials and biomedical engineering* 9 (2004) 910. DOI:10.1201/b18990-
702 161
- 703 [5] J. M. t. Daniel, P. A. Bernard, S. C. Skinner, P. Bhandary, A. Ruzic, M. K. Bacon, H.
704 O. Ballard, Hollow fiber oxygenator composition has a significant impact on failure rates in
705 neonates on extracorporeal membrane oxygenation: A retrospective analysis, *J Pediatr*
706 *Intensive Care* 7 (1) (2018) 7–13. <https://doi.org/10.1055/s-0037-1599150>
- 707 [6] C. M. Zimmerman, A. Singh, W. J. Koros, Tailoring mixed matrix composite membranes
708 for gas separations, *Journal of Membrane Science* 137 (1) (1997) 145–154.
709 [https://doi.org/10.1016/S0376-7388\(97\)00194-4](https://doi.org/10.1016/S0376-7388(97)00194-4)
- 710 [7] L. W. Lund, B. G. Hattler, W. J. Federspiel, Is condensation the cause of plasma leakage
711 in microporous hollow fiber membrane oxygenators, *Journal of Membrane Science* 147 (1)
712 (1998) 87–93. [https://doi.org/10.1016/S0376-7388\(98\)00121-5](https://doi.org/10.1016/S0376-7388(98)00121-5)
- 713 [8] B. P. Nguyen Thi, B. T. Duy Nguyen, I.-S. Jeong, J. F. Kim, Hemocompatibility
714 challenge of membrane oxygenator for artificial lung technology, *Acta Biomaterialia* 152
715 (2022) 19–46. <https://doi.org/10.1016/j.actbio.2022.09.003>
- 716 [9] Y. Feng, Q. Wang, L. Zhi, S. Sun, C. Zhao, Anticoagulant biomimetic consecutive gas
717 exchange network for advanced artificial lung membrane, *Journal of Membrane Science* 653
718 (2022) 120502. <https://doi.org/10.1016/j.memsci.2022.120502>
- 719 [10] L. Zhi, S. Li, X. He, Y. Feng, C. Cheng, S. Li, S. Sun, C. Zhao, In-situ modified
720 polyethersulfone oxygenation membrane with improved hemocompatibility and gas transfer
721 efficiency, *Journal of Membrane Science* 667 (2023) 121162.
722 <https://doi.org/10.1016/j.memsci.2022.121162>

- 723 [11] F. Hesselmann, N. Scherenberg, P. Bongartz, S. Djeljadini, M. Wessling, C. Cornelissen, T.
724 Schmitz-Rode, U. Steinseifer, S. V. Jansen, J. Arens, Structure-dependent gas transfer
725 performance of 3D-membranes for artificial membrane lungs, *Journal of Membrane Science*
726 634 (2021) 119371. <https://doi.org/10.1016/j.memsci.2021.119371>
- 727 [12] Rv, E. K. Bassett, D. M. Hoganson, J. P. Vacanti, K. K. Gleason, Ultra-thin, gas permeable
728 free-standing and composite membranes for microfluidic lung assist devices, *Biomaterials* 32
729 (16) (2011) 3883–3889. <https://doi.org/10.1016/j.biomaterials.2011.02.017>
- 730 [13] R. Bagherzadeh, S. S. Najar, M. Latifi, M. A. Tehran, L. Kong, A theoretical analysis and
731 prediction of pore size and pore size distribution in electrospun multilayer nanofibrous materials,
732 *Journal of Biomedical Materials Research Part A* 101A (7) (2013) 2107–2117.
733 <https://doi.org/10.1002/jbm.a.34487>
- 734 [14] D. Li, M. W. Frey, Y. L. Joo, Characterization of nanofibrous membranes with capillary flow
735 porometry, *Journal of Membrane Science* 286 (1) (2006) 104–114.
736 <https://doi.org/10.1016/j.memsci.2006.09.020>
- 737 [15] S. Lee, S. K. Obendorf, Use of electrospun nanofiber web for protective textile materials as
738 barriers to liquid penetration, *Textile research journal* 77 (9) (2007) 696–702.
739 <https://doi.org/10.1177/0040517507080284>
- 740 [16] S. Soliman, S. Pagliari, A. Rinaldi, G. Forte, R. Fiaccavento, F. Pagliari, O. Franzese, M.
741 Minieri, P. Di Nardo, S. Licocchia, E. Traversa, Multiscale three-dimensional scaffolds for
742 soft tissue engineering via multimodal electrospinning, *Acta Biomaterialia* 6 (4) (2010) 1227–
743 1237. <https://doi.org/10.1016/j.actbio.2009.10.051>
- 744 [17] F.-L. He, D.-W. Li, J. He, Y.-Y. Liu, F. Ahmad, Y.-L. Liu, X. Deng, Y.-J. Ye, D.-C. Yin,
745 A novel layer-structured scaffold with large pore sizes suitable for 3D cell culture prepared
746 by near-field electrospinning, *Materials Science and Engineering: C* 86 (2018) 18–27.
747 <https://doi.org/10.1016/j.msec.2017.12.016>
- 748 [18] X. Huang, W. Wang, Z. Zheng, W. Fan, C. Mao, J. Shi, L. Li, Surface monofunctionalized
749 polymethyl pentene hollow fiber membranes by plasma treatment and hemocompatibility
750 modification for membrane oxygenators, *Applied Surface Science* 362 (2016) 355–363.
751 <https://doi.org/10.1016/j.apsusc.2015.11.236>
- 752 [19] Y. Liu, G. Li, Q. Han, H. Lin, Q. Li, J. Hua, F. Liu, Anticoagulant dialyzer with enhanced
753 Ca^{2+} chelation and hydrophilicity for heparin free hemodialysis, *Journal of Membrane*
754 *Science* 604 (2020) 118082. <https://doi.org/10.1016/j.memsci.2020.118082>
- 755 [20] T. Oto, F. Rosenfeldt, M. Rowland, A. Pick, M. Rabinov, A. Prevolos, G. Snell, T. Williams,
756 D. Esmore, Extracorporeal membrane oxygenation after lung transplantation: Evolving
757 technique improves outcomes, *The Annals of Thoracic Surgery* 78 (4) (2004) 1230–1235.

- 758 <https://doi.org/10.1016/j.athoracsur.2004.03.095>
- 759 [21] Y. Shen, W. Zhao, K. Xiao, X. Huang, A systematic insight into fouling propensity of
760 soluble microbial products in membrane bioreactors based on hydrophobic interaction and
761 size exclusion, *Journal of Membrane Science* 346 (1) (2010) 187–193.
762 <https://doi.org/10.1016/j.memsci.2009.09.040>
- 763 [22] W. Zimmerli, P. Sendi, Pathogenesis of implant-associated infection: the role of the host, *Seminars*
764 *in Immunopathology* 33 (3) (2011) 295–306. <https://doi.org/10.1007/s00281-011-0275-7>
- 765 [23] I. H. Jaffer, J. C. Fredenburgh, J. Hirsh, J. I. Weitz, Medical device-induced thrombosis:
766 what causes it and how can we prevent it?, *Journal of Thrombosis and Haemostasis* 13
767 (S1) (2015) S72–S81. <https://doi.org/10.1111/jth.12961>
- 768 [24] M. B. Gorbet, M. V. Sefton, Biomaterial-associated thrombosis: roles of coagulation factors,
769 complement, platelets and leukocytes, *Biomaterials* 25 (26) (2004) 5681–5703.
770 <https://doi.org/10.1016/j.biomaterials.2004.01.023>
- 771 [25] Y. Wang, Y. Liu, Q. Han, H. Lin, F. Liu, A novel poly (4-methyl-1-
772 pentene)/polypropylene (PMP/PP) thin film composite (TFC) artificial lung membrane for
773 enhanced gas transport and excellent hemo-compatibility, *Journal of Membrane Science*
774 649 (2022) 120359. <https://doi.org/10.1016/j.memsci.2022.120359>
- 775 [26] E. Yi, H. S. Kang, S. M. Lim, H. J. Heo, D. Han, J. F. Kim, A. Park, D. H. Choi,
776 Y.-I. Park, H. Park, Y. H. Cho, E.-H. Sohn, Superamphiphobic blood-repellent surface
777 modification of porous fluoropolymer membranes for blood oxygenation applications, *Journal of*
778 *Membrane Science* 648 (2022) 120363. <https://doi.org/10.1016/j.memsci.2022.120363>
- 779 [27] A. Ontaneda, G. M. Annich, Novel surfaces in extracorporeal membrane oxygenation
780 circuits, *Frontiers in Medicine* 5 (2018). <https://doi.org/10.3389/fmed.2018.00321>
- 781 [28] M. Zhang, C. H. H. Chan, J. P. Pauls, C. Semenzin, C. Ainola, H. Peng, C. Fu, A. K.
782 Whittaker, S. Heinsar, J. F. Fraser, Investigation of heparin-loaded poly (ethylene glycol)-
783 based hydrogels as antithrombogenic surface coatings for extracorporeal membrane
784 oxygenation, *Journal of Materials Chemistry B* 10 (26) (2022) 4974–4983.
785 <http://dx.doi.org/10.1039/D2TB00379A>
- 786 [29] M. Pieri, O. G. Turla, M. G. Calabrò, L. Ruggeri, N. Agracheva, A. Zangrillo, F. Pappalardo,
787 A new phosphorylcholine-coated poly-methyl pentene oxygenator for extracorporeal
788 membrane oxygenation: a preliminary experience, *Perfusion* 28 (2) (2013) 132–7.
789 <https://doi.org/10.1177/0267659112469642>
- 790 [30] H. Suhara, Y. Sawa, M. Nishimura, H. Oshiyama, K. Yokoyama, N. Saito, H. Matsuda,
791 Efficacy of a new coating material, PMEAC, for cardiopulmonary bypass circuits in a porcine
792 model, *The Annals of Thoracic Surgery* 71 (5) (2001) 1603–1608.

- 793 [https://doi.org/10.1016/S0003-4975\(01\)02466-3](https://doi.org/10.1016/S0003-4975(01)02466-3)
- 794 [31] T. He, S. Yu, J. He, D. Chen, J. Li, H. Hu, X. Zhong, Y. Wang, Z. Wang, Z.
795 Cui, Membranes for extracorporeal membrane oxygenator (ECMO): History, preparation,
796 modification and mass transfer, *Chinese Journal of Chemical Engineering* 49 (2022) 46–75.
797 <https://doi.org/10.1016/j.cjche.2022.05.027>
- 798 [32] X. Yao, Y. Liu, Z. Chu, W. Jin, Membranes for the life sciences and their future roles in
799 medicine, *Chinese Journal of Chemical Engineering* 49 (2022) 1–20.
800 <https://doi.org/10.1016/j.cjche.2022.04.027>
- 801 [33] T. He, J. He, Z. Wang, Z. Cui, Modification strategies to improve the membrane
802 hemocompatibility in extracorporeal membrane oxygenator(ECMO), *Advanced Composites and*
803 *Hybrid Materials* 4 (4) (2021) 847– 864. <https://doi.org/10.1007/s42114-021-00244-x>
- 804 [34] L.-L. Bao, H.-Q. Huang, J. Zhao, K. Nakashima, Y.-K. Gong, Preparation and
805 characterization of zwitterionic phospholipid polymer- coated poly (lactic acid)
806 nanoparticles, *Journal of Biomaterials Science, Polymer Edition* 25 (14-15) (2014) 1703–
807 1716. <https://doi.org/10.1080/09205063.2014.952993>
- 808 [35] H. C. Barshilia, N. Gupta, Superhydrophobic polytetrafluoroethylene surfaces with leaf-like
809 micro-protrusions through Ar + O₂ plasma etching process, *Vacuum* 99 (2014) 42–48.
810 <https://doi.org/10.1016/j.vacuum.2013.04.020>
- 811 [36] S. Rezaei, I. Manoucheri, R. Moradian, B. Pourabbas, One-step chemical vapor deposition
812 and modification of silica nanoparticles at the lowest possible temperature and superhydrophobic
813 surface fabrication, *Chemical Engineering Journal* 252 (2014) 11–16.
814 <https://doi.org/10.1016/j.cej.2014.04.100>
- 815 [37] K.-J. Lu, C. Z. Liang, Y. Chen, T.-S. Chung, Unlock the secret of air blowing in
816 developing high strength and superhydrophobic membranes for membrane distillation,
817 *Desalination* 527 (2022) 115579. <https://doi.org/10.1016/j.desal.2022.115579>
- 818 [38] X. Wang, B. Ding, J. Yu, M. Wang, Engineering biomimetic superhydrophobic surfaces of
819 electrospun nanomaterials, *Nano Today* 6 (5) (2011) 510–530.
820 <https://doi.org/10.1016/j.nantod.2011.08.004>
- 821 [39] Q. Liu, H. Wang, L. Chen, W. Li, Y. Zong, Y. Sun, Z. Li, Enzymatic degradation of
822 fluorinated poly(ϵ -caprolactone) (PCL) block copolymer films with improved
823 hydrophobicity, *Polymer Degradation and Stability* 165 (2019) 27–34.
824 <https://doi.org/10.1016/j.polymdegradstab.2019.04.018>
- 825 [40] M. Milosevic, D. B. Stojanovic, V. Simic, M. Grkovic, M. Bjelovic, P. S. Uskokovic,
826 M. Kojic, Preparation and modeling of three-layered PCL/PLGA/PCL fibrous scaffolds for
827 prolonged drug release, *Scientific Reports* 10 (1) (2020) 11126.

- 828 <https://doi.org/10.1038/s41598-020-68117-9>
- 829 [41] K. R. Ammann, S. F. A. Hossainy, S. Hossainy, M. J. Slepian, Hemocompatibility of
830 polymers for use in vascular endoluminal implants, *Journal of Applied Polymer Science*
831 138 (43) (2021) 51277. <https://doi.org/10.1002/app.51277>
- 832 [42] E. Saracino, V. Cirillo, M. Marrese, V. Guarino, V. Benfenati, R. Zamboni, L. Ambrosio,
833 Structural and functional properties of astrocytes on PCL based electrospun fibres, *Materials*
834 *Science and Engineering: C* 118 (2021) 111363. <https://doi.org/10.1016/j.msec.2020.111363>
- 835 [43] X. Deng, M. Gould, M. A. Ali, Fabrication and characterisation of melt-extruded
836 chitosan/keratin/PCL/PEG drug-eluting sutures designed for wound healing, *Materials*
837 *Science and Engineering: C* 120 (2021) 111696. <https://doi.org/10.1016/j.msec.2020.111696>
- 838 [44] S. Park, J. Kim, M.-K. Lee, C. Park, H.-D. Jung, H.-E. Kim, T.-S. Jang, Fabrication of strong,
839 bioactive vascular grafts with PCL/collagen and PCL/silica bilayers for small-diameter
840 vascular applications, *Materials Design* 181 (2019) 108079.
841 <https://doi.org/10.1016/j.matdes.2019.108079>
- 842 [45] H. Kuang, Y. Wang, Y. Shi, W. Yao, X. He, X. Liu, X. Mo, S. Lu, P. Zhang,
843 Construction and performance evaluation of Hep/silk-PLCL composite nanofiber small-
844 caliber artificial blood vessel graft, *Biomaterials* 259 (2020) 120288.
845 <https://doi.org/10.1016/j.biomaterials.2020.120288>
- 846 [46] D. Liu, W. Nie, D. Li, W. Wang, L. Zheng, J. Zhang, J. Zhang, C. Peng, X. Mo,
847 C. He, 3D printed PCL/SrHA scaffold for enhanced bone regeneration, *Chemical*
848 *Engineering Journal* 362 (2019) 269–279. <https://doi.org/10.1016/j.cej.2019.01.015>
- 849 [47] A. K. Maparu, P. Singh, B. Rai, A. Sharma, S. Sivakumar, A simple, robust and scalable route
850 to prepare sub-50 nm soft PDMS nanoparticles for intracellular delivery of anticancer drugs,
851 *Nanotechnology* 33 (49) (2022) 495102. <https://dx.doi.org/10.1088/1361-6528/ac8d99>
- 852 [48] M. Ge, C. Cao, F. Liang, R. Liu, Y. Zhang, W. Zhang, T. Zhu, B. Yi, Y. Tang, Y.
853 Lai, A “PDMS-in-water” emulsion enables mechanochemically robust superhydrophobic
854 surfaces with self-healing nature, *Nanoscale Horizons* 5 (1) (2020) 65–73.
855 <http://dx.doi.org/10.1039/C9NH00519F>
- 856 [49] S.-W. Jeong, S. Bolortuya, S. B. Eadi, S. Kim, Fabrication of superhydrophobic surfaces
857 based on PDMS coated hydrothermal grown ZnO on PET fabrics, *Journal of Adhesion*
858 *Science and Technology* 34 (1) (2020) 102–113.
859 <https://doi.org/10.1080/01694243.2019.1661609>
- 860 [50] X. Q. Cheng, Y. Jiao, Z. Sun, X. Yang, Z. Cheng, Q. Bai, Y. Zhang, K. Wang, L.
861 Shao, Constructing scalable superhydrophobic membranes for ultrafast water–oil separation,
862 *ACS Nano* 15 (2) (2021) 3500–3508. <https://doi.org/10.1021/acsnano.1c00158>

- 863 [51] X. Zhang, B. Du, Y. Dai, W. Zheng, X. Ruan, G. He, Hemocompatible
864 polydimethylsiloxane/polysulfone ultrathin composite membrane for extracorporeal
865 membrane oxygenation, *Separation and Purification Technology* 302 (2022) 122028.
866 <https://doi.org/10.1016/j.seppur.2022.122028>
- 867 [52] A. Park, Y. Song, E. Yi, B. T. Duy Nguyen, D. Han, E. Sohn, Y. Park, J. Jung, Y.
868 M. Lee, Y. H. Cho, J. F. Kim, Blood oxygenation using fluoropolymer-based artificial lung
869 membranes, *ACS Biomaterials Science Engineering* 6 (11) (2020) 6424–6434.
870 <https://doi.org/10.1021/acsbmaterials.0c01251>
- 871 [53] D. Dixit, C. Ghoroi, Role of randomly distributed nanoscale roughness for designing highly
872 hydrophobic particle surface without using low surface energy coating, *Journal of Colloid*
873 *and Interface Science* 564 (2020) 8–18. <https://doi.org/10.1016/j.jcis.2019.12.041>
- 874 [54] M. J. Owen, Low surface energy inorganic polymers, *Comments on Inorganic Chemistry* 7 (4)
875 (1988) 195–213. <https://doi.org/10.1080/02603598808072308>
- 876 [55] P. Roach, D. Farrar, C. C. Perry, Interpretation of protein adsorption: surface-induced
877 conformational changes, *Journal of the American Chemical Society* 127 (22) (2005) 8168–
878 8173. <https://doi.org/10.1021/ja042898o>
- 879 [56] T. R. Roberts, M. R. S. Garren, H. Handa, A. I. Batchinsky, Toward an artificial
880 endothelium: Development of blood-compatible surfaces for extracorporeal life support, *J*
881 *Trauma Acute Care Surg* 89 (2S Suppl 2) (2020) S59–s68.
882 <https://doi.org/10.1097/TA.0000000000002700>
- 883 [57] D. J. Weiss, *Comparative Physiology of Platelets from Different Species*, Springer US,
884 Boston, MA, 1999, pp. 379–393.
- 885 [58] J. Linneweber, P. M. Dohmen, U. Kerzschner, K. Affeld, Y. Noše, W. Konertz, The effect of surface
886 roughness on activation of the coagulation system and platelet adhesion in rotary blood pumps,
887 *Artificial Organs* 31 (5) (2007) 345–351, <https://doi.org/10.1111/j.1525-1594.2007.00391.x>
- 888 [59] A. A. Rownaghi, D. Bhandari, S. K. Burgess, D. S. Mikkilineni, Effects of coating solvent and
889 thermal treatment on transport and morphological characteristics of PDMS/Torlon composite
890 hollow fiber membrane, *Journal of Applied Polymer Science* 134 (42) (2017) 45418,
891 <https://doi.org/10.1002/app.45418>
- 892 [60] W. Wei, S. Xia, G. Liu, X. Gu, W. Jin, N. Xu, Interfacial adhesion between polymer
893 separation layer and ceramic support for composite membrane, *AIChE Journal* 56 (6)
894 (2010) 1584–1592. <https://doi.org/10.1002/aic.12086>
- 895 [61] A. I. Hassan, A. L. Ahmad, Z. M. H. M. Shafie, N. D. Zaulkiflee, Fabrication of
896 polydimethylsiloxane (PDMS) dense layer on porous polyethersulfone (PES) hollow fibre
897 membrane with varying dip coating parameters, *Journal of Physical Science* 32 (1) (2021) 39–

- 898 56. <https://doi.org/10.21315/jps2021.32.1.4>
- 899 [62] S. M. Allen, M. Fujii, V. Stannett, H. B. Hopfenberg, J. L. Williams, The barrier properties
900 of polyacrylonitrile, *Journal of Membrane Science* 2 (1977) 153–163.
901 [https://doi.org/10.1016/S0376-7388\(00\)83241-X](https://doi.org/10.1016/S0376-7388(00)83241-X)
- 902 [63] B. T. Duy Nguyen, H. Y. Nguyen Thi, B. P. Nguyen Thi, D.-K. Kang, J. F.
903 Kim, The roles of membrane technology in artificial organs: Current challenges and
904 perspectives, *Membranes* 11 (4) (2021) 239. <https://doi.org/10.3390/membranes11040239>
- 905 [64] P. W. Blair, D. M. Brown, M. Jang, A. A. R. Antar, J. C. Keruly, V. S. Bachu, J. L.
906 Townsend, J. A. Tornheim, S. C. Keller, L. Sauer, D. L. Thomas, Y. C. Manabe, A. C.
907 S. Team, The clinical course of covid-19 in the outpatient setting: A prospective cohort
908 study, *Open Forum Infectious Diseases* 8 (2) (2021). <https://doi.org/10.1093/ofid/ofab007>

Highlights

Superhydrophobic polydimethylsiloxane dip-coated polycaprolactone electrospun membrane for extracorporeal membrane oxygenation

Zhuomin Jiang, Bao Tran Duy Nguyen, JeongHyeon Seo, Changgi Hong, Dongwoo Kim, Suhyun Ryu, Sohui Lee, Gyubok Lee, Young Hoon Cho*, Jeong F. Kim*, Kangwon Lee**

- Superhydrophobic membrane was designed for the ECMO membrane.
- PCL electrospun membrane was applied to the ECMO membrane substrate, and PDMS dip coating enhanced the surface hydrophobicity.
- The membrane had low protein adsorption under 10 *mg/mL* BSA concentrations.
- The membrane had a competitive blood oxygenation rate and hemocompatibility compared to market-dominating materials (PP and PMP).

Author statement

Superhydrophobic polydimethylsiloxane dip-coated polycaprolactone electrospun membrane for extracorporeal membrane oxygenation

Zhuomin Jiang, Bao Tran Duy Nguyen, JeongHyeon Seo, Changgi Hong, Dongwoo Kim, Suhyun Ryu, Sohui Lee, Gyubok Lee, Young Hoon Cho*, Jeong F. Kim*, Kangwon Lee**

Zhuomin Jiang: Conceptualization, Methodology, Data analysis, Writing-original draft, Writing-review & editing. **Bao Tran Duy Nguyen:** Methodology, Data analysis. **JeongHyeon Seo:** Methodology, Data analysis. **Changgi Hong:** Methodology, Data curation. **Dongwoo Kim:** Methodology, Data curation. **Suhyun Ryu:** Data curation. **Sohui Lee:** Data curation. **Gyubok Lee:** Data curation. **Young Hoon Cho:** Review & Editing, Validation, Resources. **Jeong F. Kim:** Review & Editing, Validation, Resources. **Kangwon Lee:** Supervision, Funding acquisition, Project administration.

Declaration of competing interest

Superhydrophobic polydimethylsiloxane dip-coated polycaprolactone electrospun membrane for extracorporeal membrane oxygenation

Zhuomin Jiang, Bao Tran Duy Nguyen, JeongHyeon Seo, Changgi Hong, Dongwoo Kim, Suhyun Ryu, Sohui Lee, Gyubok Lee, Young Hoon Cho*, Jeong F. Kim*, Kangwon Lee**

The authors declare no conflicts of interest.